GeoVax to Showcase Mpox Vaccine Progress at Emerging Growth Conference
GeoVax Labs, Inc. will present updates on its GEO-MVA Mpox vaccine development at the Emerging Growth Conference, highlighting potential regulatory acceleration and manufacturing advantages.
GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present at the Emerging Growth Conference on August 20, 2025. The presentation will focus on the company's GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine, and its development program. David Dodd, Chairman and CEO of GeoVax, will discuss recent progress and upcoming milestones, including the favorable Scientific Advice received from the European Medicines Agency (EMA), which could significantly accelerate the regulatory approval timeline for GEO-MVA.
The company's MVA platform and U.S.-based continuous cell line manufacturing capabilities are expected to play a crucial role in addressing vaccine supply diversification, pandemic readiness, and biosecurity. This presentation is an opportunity for shareholders and the investment community to engage directly with GeoVax's leadership during a live Q&A session. For those interested in attending the conference or receiving updates, registration is available at https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=govx.
Questions can be submitted in advance to Questions@EmergingGrowth.com or asked live during the presentation. A replay of the event will be available on www.EmergingGrowth.com and the Emerging Growth YouTube channel. This presentation underscores GeoVax's commitment to advancing vaccine development and its potential impact on global health security.